Agenda

LEARNING OBJECTIVES:

Upon completion of this program, participants will be better able to:

​

• Describe the pathophysiology, epidemiology, and risk factors associated with Metabolic dysfunction-associated steatotic liver disease (MASLD)

• Apply evidence-based screening methods to identify metabolic dysfunction–associated steatohepatitis (MASH) in at-risk populations

• Determine appropriate diagnostic recommendations for MASH and fibrosis 

• Evaluate the role of pharmacologic and non-pharmacologic strategies in the management of MASLD and its comorbidities

• Create personalized, patient-centered care plans to optimize outcomes in MASLD management